A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid

Pancreatic adenocarcinoma is a common disease considered to be poorly responsive to antiblastic treatment. Recent clinical and preclinical results suggest that a combined treatment of gemcitabine (GEM), 5-flurouracil (5-FU) and folinic acid (FA) offers a clinical benefit in patients with advanced pancreas adenocarcinoma. The aim of this phase II clinical trial was to evaluate the antitumour activity and toxicity of a novel biweekly schedule of this combination in patients with pancreatic adenocarcinoma. A total of 42 patients received a 30 min infusion of FA (100 mgm2) and 5-FU (400 mgm2) (FUFA) on days 1–3, and GEM 1000 mgm2 on day 1 every 15 days. We observed 13 objective responses (two complete, 11 partial) and 23 stable diseases. The median time to progression was 9.75 months (95% Confidence Interval (CI), 6.88–12.62) and the median overall survival was 13.10 months (95% CI 9.64–16.56). There were seven cases of each grade III gastroenteric and haematological toxicity. The GEM plus FUFA combination appears to be well tolerated and very active in patients with pancreatic carcinoma

Determinants of Bacteriophage 933W Repressor DNA Binding Specificity

We reported previously that 933W repressor apparently does not cooperatively bind to adjacent sites on DNA and that the relative affinities of 933W repressor for its operators differ significantly from that of any other lambdoid bacteriophage. These findings indicate that the operational details of the lysis-lysogeny switch of bacteriophage 933W are unique among lambdoid bacteriophages. Since the functioning of the lysis-lysogeny switch in 933W bacteriophage uniquely and solely depends on the order of preference of 933W repressor for its operators, we examined the details of how 933W repressor recognizes its DNA sites. To identify the specificity determinants, we first created a molecular model of the 933W repressor-DNA complex and tested the predicted protein-DNA interactions. These results of these studies provide a picture of how 933W repressor recognizes its DNA sites. We also show that, opposite of what is normally observed for lambdoid phages, 933W operator sequences have evolved in such a way that the presence of the most commonly found base sequences at particular operator positions serves to decrease, rather than increase, the affinity of the protein for the site. This finding cautions against assuming that a consensus sequence derived from sequence analysis defines the optimal, highest affinity DNA binding site for a protein

Measurement of the BB Meson Differential Cross Section, dσ/dpTd\sigma/dp_T, in ppˉp\bar{p} Collisions at s=1.8\sqrt{s} = 1.8 TeV

This paper presents the first direct measurement of the $B$ meson differential cross section, $d\sigma/dp_T$, in $p\bar{p}$ collisions at $\sqrt{s}=1.8$ TeV using a sample of $19.3 \pm 0.7$ pb$^{-1}$ accumulated by the Collider Detector at Fermilab (CDF). The cross section is measured in the central rapidity region $|y| 6.0$ GeV/$c$ by fully reconstructing the $B$ meson decays $B^{+}\to J/\psi K^{+}$ and $B^{0}\to J/\psi K^{*0}(892)$, where $J/\psi \to \mu^+\mu^-$ and $K^{*0} \to K^+ \pi^-$. A comparison is made to the theoretical QCD prediction calculated at next-to-leading order.Comment: 14 pages. Submitted to Phys. Rev. Lett. The postscript file is at http://www-cdf.fnal.gov/physics/pub95/cdf2893_bexcl_xsection.p

Limits on WWZWWZ and WWγWW\gamma couplings from WWWW and WZWZ production in pp‾p\overline{p} collisions at s=1.8\sqrt{s} = 1.8 TeV

Direct limits are set on $WWZ$ and $WW\gamma$ three-boson couplings in a search for $WW$ and $WZ$ production with high transverse momentum in $p\overline{p}$ collisions at $\sqrt{s} = 1.8$ TeV, using the Collider Detector at Fermilab. The results are in agreement with the SU(2) $\times$ U(1) model of electroweak interactions. Assuming Standard Model $WW\gamma$ coupling, the the limits are interpreted as direct evidence for a non-zero $WWZ$ coupling at subprocess energies near 500 GeV. Alternatively, assumiong identical $WWZ$ and $WW\gamma$ couplings, bounds $-0.11 < \kappa < 2.27$ and $-0.81 < \lambda < 0.84$ are obtained at $95\%$ CL for a form factor scale 1000 GeV.Comment: 16 pages, submitted to PRL, URL: http://www-cdf.fnal.gov/physics/pub95/cdf2951_vvprl.p

Search For Charged Higgs Decays of the Top Quark Using Hadronic Decays of the Tau Lepton

This Letter describes a direct search for charged Higgs boson production in proton-antiproton collisions at sqrt(s)=1.8 TeV recorded by the Collider Detector at Fermilab. Two-Higgs-doublet extensions to the standard model predict the existence of charged Higgs bosons. In such models, the branching fraction for top quarks B(t --> H b --> tau nu b) can be large. This search uses the hadronic decays of the tau lepton in this channel to significantly extend previous limits on charged Higgs production.Comment: 6pages, 4 figures, 1 table; LaTeX; submitted to PR

Measurement of the Top Quark Mass with the Collider Detector at Fermilab

This report describes a measurement of the top quark mass in \ppbar collisions at a center of mass energy of 1.8 TeV. The data sample was collected with the CDF detector during the 1992--95 collider run at the Fermilab Tevatron, and corresponds to an integrated luminosity of 106 \pb. Candidate $t\bar{t}$ events in the ``lepton+jets'' decay channel provide our most precise measurement of the top quark mass. For each event a top mass is determined by using energy and momentum constraints on the production of the \ttbar pair and its subsequent decay. A likelihood fit to the distribution of reconstructed masses in the data sample gives a top mass in the lepton+jets channel of 176.1\pm 5.1 (stat.)\pm 5.3 (syst.) \gevcc. Combining this result with measurements from the ``all-hadronic'' and ``dilepton'' decay topologies yields a top mass of 176.1\pm 6.6 \gevcc.Comment: 158 pages, 41 figure

Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer

Because only 16% of patients with metastatic cervical cancer are alive 5 years after diagnosis, the Gynecologic Oncology Group (GOG) has carefully designed and conducted many phase II studies to identify promising drugs. Cisplatin has emerged as the most active single agent with overall response rates of 19%. Recent phase III trials have documented response rates of 27% and 39% when cisplatin has been combined with either paclitaxel or topotecan, respectively. The comparison of cisplatin to cisplatin plus topotecan in GOG-179 has yielded the first study to show a statistically significant impact on the overall response rate, median progression-free survival, and median survival, with all outcome measures favoring the two-drug regimen. Despite these encouraging results, however, most of the responses are partial and of short duration. The need for novel combinations and the implementation of active biologic agents is implicit. The accumulated data in this disease setting, as evidenced by the experience of the GOG, are presented in this review